Abstract:The HIV-1 CA protein has gained remarkable attention as a promising therapeutic target for the development of new antivirals, due to its pivotal roles in HIV-1 replication (structural and regulatory). Herein, we report the design and synthesis of three series of benzenesulfonamide-containing phenylalanine derivatives obtained by further structural modifications of PF-74 to aid in the discovery of more potent and drug-like HIV-1 CA inhibitors. Structure-activity relationship studies of these compounds led to the identification of new phenylalanine derivatives with a piperazinone moiety, represented by compound 11l, which exhibited anti-HIV-1(NL4-3) activity 5.78-fold better than PF-74. Interestingly, 11l also showed anti-HIV-2(ROD) activity (EC50 = 31 nM), with almost 120 times increased potency over PF-74. However, due to the higher significance of HIV-1 as compared to HIV-2 for the human population, this manuscript focuses on the mechanism of action of our compounds in the context of HIV-1. SPR studies on representative compounds confirmed CA as the binding target. The action stage determination assay demonstrated that these inhibitors exhibited antiviral activities with a dual-stage inhibition profile. The early-stage inhibitory activity of compound 11l was 6.25 times more potent as compared to PF-74 but appeared to work via the accelerating capsid core assembly rather than stabilization. However, the mechanism by which they exert their antiviral activity in the late stage appears to be the same as PF-74 with less infectious HIV-1 virions produced in their presence, as judged p24 content studies. MD simulations provided the key rationale for the promising antiviral potency of 11l. Additionally, 11l exhibited a modest increase in HLM and human plasma metabolic stabilities as compared to PF-74, as well as a moderately improved pharmacokinetic profile, favorable oral bioavailability, and no acute toxicity. These studies provide insights and serve as a starting point for subsequent medicinal chemistry efforts in optimizing these promising HIV inhibitors.

Toward Structurally Novel and Metabolically Stable HIV-1 Capsid-Targeting Small Molecules

Chemical Profiling of HIV-1 Capsid-Targeting Antiviral PF74.

Design, Synthesis and Characterization of HIV-1 CA-Targeting Small Molecules: Conformational Restriction of PF74

Novel HIV-1 Capsid-Targeting Small Molecules of the PF74 Binding Site.

Discovery of low‐molecular‐weight phenylalanine derivatives as novel HIV capsid modulators with improved antiretroviral activity and metabolic stability

Design, Synthesis, and Mechanistic Investigations of Phenylalanine Derivatives Containing a Benzothiazole Moiety As HIV-1 Capsid Inhibitors with Improved Metabolic Stability

Design, Synthesis and Structure—Activity Relationships of Phenylalanine-Containing Peptidomimetics As Novel HIV-1 Capsid Binders Based on Ugi Four-Component Reaction

Design, Synthesis, and Mechanism Study of Dimerized Phenylalanine Derivatives As Novel HIV-1 Capsid Inhibitors.

From Design to Biological Mechanism Evaluation of Phenylalanine-Bearing HIV-1 Capsid Inhibitors Targeting a Vital Assembly Interface

Design, Synthesis, and Mechanistic Study of 2-Pyridone-bearing Phenylalanine Derivatives As Novel HIV Capsid Modulators

Design, Synthesis and Structure-Activity Relationships of 4-Phenyl-1h-1,2,3-triazole Phenylalanine Derivatives As Novel HIV-1 Capsid Inhibitors with Promising Antiviral Activities.

Discovery of Novel 1,4-Disubstituted 1,2,3-Triazole Phenylalanine Derivatives As HIV-1 Capsid Inhibitors

Discovery and Mechanistic Investigation of Piperazinone Phenylalanine Derivatives with Terminal Indole or Benzene Ring as Novel HIV-1 Capsid Modulators

Discovery of Phenylalanine Derivatives As Potent HIV-1 Capsid Inhibitors from Click Chemistry-Based Compound Library.

Design and Synthesis of New GS-6207 Subtypes for Targeting HIV-1 Capsid Protein

Quinazolinone-based subchemotypes for targeting HIV-1 capsid protein: design and synthesis

Design, synthesis, and antiviral activity of phenylalanine derivatives as HIV-1 capsid inhibitors

Low-molecular-weight anti-HIV-1 agents targeting HIV-1 capsid proteins

Discovery of Novel 1,2,4‐triazole Phenylalanine Derivatives Targeting an Unexplored Region Within the Interprotomer Pocket of the HIV Capsid Protein

Potent Long-Acting Inhibitors Targeting the HIV-1 Capsid Based on a Versatile Quinazolin-4-one Scaffold

Discovery, Crystallographic Studies, and Mechanistic Investigations of Novel Phenylalanine Derivatives Bearing a Quinazolin-4-one Scaffold as Potent HIV Capsid Modulators